BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baek JH, Sun JM, Min YJ, Cho EK, Cho BC, Kim JH, Ahn MJ, Park K. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. Lung Cancer. 2015;87:148-154. [PMID: 25498243 DOI: 10.1016/j.lungcan.2014.11.013] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Li H, Wang C, Wang Z, Hu Y, Zhang G, Zhang M, Zheng X, Zhang X, Yang J, Ma Z, Wang H. Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy. Lung Cancer 2019;130:42-9. [PMID: 30885350 DOI: 10.1016/j.lungcan.2019.02.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
2 Prabhash K. Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update. South Asian J Cancer 2019;8:1-17. [PMID: 30766843 DOI: 10.4103/sajc.sajc_227_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
3 Su J, Zhong W, Zhang X, Huang Y, Yan H, Yang J, Dong Z, Xie Z, Zhou Q, Huang X, Lu D, Yan W, Wu YL. Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients. Oncotarget 2017;8:111246-57. [PMID: 29340050 DOI: 10.18632/oncotarget.22768] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
4 Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol 2020;61:167-79. [PMID: 31562956 DOI: 10.1016/j.semcancer.2019.09.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 13.3] [Reference Citation Analysis]
5 Castellanos E, Feld E, Horn L. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer. Journal of Thoracic Oncology 2017;12:612-23. [DOI: 10.1016/j.jtho.2016.12.014] [Cited by in Crossref: 79] [Cited by in F6Publishing: 87] [Article Influence: 15.8] [Reference Citation Analysis]
6 Passaro A, Mok T, Peters S, Popat S, Ahn MJ, de Marinis F. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. J Thorac Oncol 2021;16:764-73. [PMID: 33333327 DOI: 10.1016/j.jtho.2020.12.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
7 Zhang W, Lin X, Li X, Wang M, Sun W, Han X, Sun D. Survival prediction model for non-small cell lung cancer based on somatic mutations. J Gene Med 2020;22:e3206. [PMID: 32367667 DOI: 10.1002/jgm.3206] [Reference Citation Analysis]
8 Torri V, Broggini M, Garassino MC. EGFR mutations and EGFR tyrosine kinase inhibitors. Lancet Oncol 2015;16:746-8. [PMID: 26051233 DOI: 10.1016/S1470-2045(15)00028-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Guan H, Du Y, Ning Y, Cao X. A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants. Future Medicinal Chemistry 2017;9:693-704. [DOI: 10.4155/fmc-2016-0222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. Cancer Res Treat 2019;51:502-9. [PMID: 29898592 DOI: 10.4143/crt.2018.117] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
11 Sehgal K, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist 2021;26:281-7. [PMID: 32969527 DOI: 10.1002/onco.13537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rana R, Rathi V, Chauhan K, Jain K, Chhabra SS, Acharya R, Kalra SK, Gupta A, Jain S, Ganguly NK, Yadav DK. Exploring the role of epidermal growth factor receptor variant III in meningeal tumors. PLoS One 2021;16:e0255133. [PMID: 34582442 DOI: 10.1371/journal.pone.0255133] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Frega S, Lorenzi M, Fassan M, Indraccolo S, Calabrese F, Favaretto A, Bonanno L, Polo V, Zago G, Lunardi F, Attili I, Pavan A, Rugge M, Guarneri V, Conte P, Pasello G. Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget 2017;8:32626-38. [PMID: 28427238 DOI: 10.18632/oncotarget.15945] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
14 Wang S, Li J. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. Onco Targets Ther 2019;12:6535-48. [PMID: 31496745 DOI: 10.2147/OTT.S198945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
15 Zhang Y, Chen G, Chen X, Fang W, Gao F, Yang Y, Zhao Y, Ma Y, Hong S, Zhang Z, Miao S, Wu M, Huang X, Luo Y, Zhou C, Gong R, Huang Y, Chen L, Zhou N, Zhao H, Zhang L. The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer. J Cancer 2017;8:1865-71. [PMID: 28819384 DOI: 10.7150/jca.19867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
16 He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335 [PMID: 33644199 DOI: 10.12998/wjcc.v9.i6.1329] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Masri M, Mcmanus M, Mudad R. Treatment of Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapy. Curr Pulmonol Rep 2018;7:79-91. [DOI: 10.1007/s13665-018-0204-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chelabi S, Mignard X, Leroy K, Monnet I, Brosseau S, Theou-Anton N, Massiani MA, Friard S, Duchemann B, Fabre E, Giroux-Leprieur E, Cadranel J, Wislez M. EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. Cancers (Basel) 2021;13:5132. [PMID: 34680280 DOI: 10.3390/cancers13205132] [Reference Citation Analysis]
19 Wang M, Ren D, Guo C, Ding X, Wang H. [Clinical Features of EGFR Double Mutation in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2018;21:594-9. [PMID: 30172266 DOI: 10.3779/j.issn.1009-3419.2018.08.05] [Reference Citation Analysis]
20 Li K, Yang M, Liang N, Li S. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). Oncol Rep 2017;37:1347-58. [PMID: 28184913 DOI: 10.3892/or.2017.5409] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
21 Chang GC, Yang TY, Chen KC, Hsu KH, Huang YH, Su KY, Yu SL, Tseng JS. ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Sci Rep 2020;10:21063. [PMID: 33273548 DOI: 10.1038/s41598-020-78152-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Int J Mol Sci 2019;20:E1431. [PMID: 30901844 DOI: 10.3390/ijms20061431] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
23 Zhang C, Lin L, Zuo R, Wang Y, Chen P. Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review. Thorac Cancer 2020;11:2743-8. [PMID: 32776462 DOI: 10.1111/1759-7714.13606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
24 Wang WJ, Zhang T. Integration of traditional Chinese medicine and Western medicine in the era of precision medicine. J Integr Med 2017;15:1-7. [PMID: 28088253 DOI: 10.1016/S2095-4964(17)60314-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
25 Wu SG, Yu CJ, Yang JC, Shih JY. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation.Ther Adv Med Oncol. 2020;12:1758835920946156. [PMID: 32843903 DOI: 10.1177/1758835920946156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Liu HL, Han G, Peng M, Weng YM, Yuan JP, Yang GF, Yu JM, Song QB. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. J Huazhong Univ Sci Technolog Med Sci 2017;37:864-72. [PMID: 29270745 DOI: 10.1007/s11596-017-1819-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
27 Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin A, Spleiss O, Wu L, Shames DS. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. Journal of Thoracic Oncology 2016;11:545-55. [DOI: 10.1016/j.jtho.2015.12.107] [Cited by in Crossref: 51] [Cited by in F6Publishing: 58] [Article Influence: 8.5] [Reference Citation Analysis]
28 Jing C, Mao X, Wang Z, Sun K, Ma R, Wu J, Cao H. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer. Mol Med Rep 2018;18:2191-7. [PMID: 29956783 DOI: 10.3892/mmr.2018.9210] [Cited by in Crossref: 9] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
29 Tarigopula A, Ramasubban G, Chandrashekar V, Govindasami P, Chandran C. EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India. Cancer Rep (Hoboken) 2020;3:e1288. [PMID: 32881404 DOI: 10.1002/cnr2.1288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, Sørensen JB. Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers (Basel) 2019;11:E923. [PMID: 31266248 DOI: 10.3390/cancers11070923] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
31 Jiang W, Ji M. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. Semin Cancer Biol 2019;59:3-22. [PMID: 30943434 DOI: 10.1016/j.semcancer.2019.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
32 Du W, Wo Y, Lu T, Wang Y, Jiao W. [A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer
with Uncommon EGFR Mutations]. Zhongguo Fei Ai Za Zhi 2019;22:590-9. [PMID: 31526464 DOI: 10.3779/j.issn.1009-3419.2019.09.07] [Reference Citation Analysis]
33 Singh V, Nambirajan A, Malik PS, Thulkar S, Pandey RM, Luthra K, Arava S, Ray R, Mohan A, Jain D. Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India. Lung Cancer 2020;149:53-60. [PMID: 32971387 DOI: 10.1016/j.lungcan.2020.07.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Liang C, Wu Z, Gan X, Liu Y, You Y, Liu C, Zhou C, Liang Y, Mo H, Chen AM, Zhang J. Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing. Yonsei Med J 2018;59:13-9. [PMID: 29214771 DOI: 10.3349/ymj.2018.59.1.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
35 Yu X, Zhang X, Zhang Z, Lin Y, Wen Y, Chen Y, Wang W, Zhang L. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience. Cancer Commun (Lond) 2018;38:51. [PMID: 30055651 DOI: 10.1186/s40880-018-0321-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
36 Lv L, Liu Z, Liu Y, Zhang W, Jiang L, Li T, Lu X, Lei X, Liang W, Lin J. Distinct EGFR Mutation Pattern in Patients With Non-Small Cell Lung Cancer in Xuanwei Region of China: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:519073. [PMID: 33224870 DOI: 10.3389/fonc.2020.519073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Xu X, Yang Y, Li H, Chen Z, Jiang G, Fei K. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing. Scand J Clin Lab Invest 2016;76:386-92. [PMID: 27215271 DOI: 10.1080/00365513.2016.1183813] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
38 Masood A, Kancha RK, Subramanian J. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Semin Oncol 2019;46:271-83. [PMID: 31558282 DOI: 10.1053/j.seminoncol.2019.08.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
39 O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer 2017;109:137-44. [PMID: 28577943 DOI: 10.1016/j.lungcan.2017.04.016] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 11.6] [Reference Citation Analysis]
40 Yamamoto G, Kikuchi M, Kobayashi S, Arai Y, Fujiyoshi K, Wakatsuki T, Kakuta M, Yamane Y, Iijima Y, Mizutani H, Nakajima Y, Sudo J, Kinoshita H, Kurimoto F, Akiyama H, Uramoto H, Sakai H, Akagi Y, Akagi K. Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing. Int J Oncol 2017;50:1579-89. [PMID: 28350094 DOI: 10.3892/ijo.2017.3935] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
41 Shi Y, Li P, Li B, Zhang F, Huang S, Shen S, Li X. [Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them]. Zhongguo Fei Ai Za Zhi 2019;22:299-305. [PMID: 31109439 DOI: 10.3779/j.issn.1009-3419.2019.05.06] [Reference Citation Analysis]
42 Chang HC, Chen YM, Tseng CC, Huang KT, Wang CC, Chen YC, Lai CH, Fang WF, Kao HC, Lin MC. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Tumour Biol 2017;39:1010428317695939. [PMID: 28351317 DOI: 10.1177/1010428317695939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y, Wu D, Lou Y, Zhang X, Wang H, Han B. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Lung Cancer 2016;96:87-92. [DOI: 10.1016/j.lungcan.2016.01.018] [Cited by in Crossref: 34] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
44 Li HS, Zhang JY, Yan X, Xu HY, Hao XZ, Xing PY, Wang Y. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations. Cancer Med 2022. [PMID: 35023313 DOI: 10.1002/cam4.4495] [Reference Citation Analysis]
45 Roca E, Gurizzan C, Amoroso V, Vermi W, Ferrari V, Berruti A. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. Cancer Treat Rev. 2017;59:117-122. [PMID: 28806542 DOI: 10.1016/j.ctrv.2017.07.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
46 Shen CI, Ho HL, Yeh YC, Chiu CH, Chou TY. Epidermal growth factor receptor mutations in non-small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction-based assays. J Chin Med Assoc 2020;83:345-9. [PMID: 32101894 DOI: 10.1097/JCMA.0000000000000277] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. Clinical Lung Cancer 2018;19:93-104. [DOI: 10.1016/j.cllc.2017.05.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
48 Vestergaard HH, Christensen MR, Lassen UN. A systematic review of targeted agents for non-small cell lung cancer. Acta Oncol 2018;57:176-86. [PMID: 29172833 DOI: 10.1080/0284186X.2017.1404634] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
49 Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C, Chiari R, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, Cappuzzo F, de Marinis F. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. Clin Lung Cancer 2019;20:e186-94. [PMID: 30563752 DOI: 10.1016/j.cllc.2018.11.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
50 Yang W, Gao Y, Li X, Zhang J, Liu T, Feng X, Pan H, Yang X, Xie S, Feng X, Lv Z, Wang Y, Chen Z, He J. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study. World J Surg Oncol 2017;15:197. [PMID: 29110716 DOI: 10.1186/s12957-017-1251-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
51 Zeng Y, Guo T, Zhou Y, Zhao Y, Chu L, Chu X, Yang X, Ni J, Zhu Z. Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters. BMC Cancer 2022;22:198. [PMID: 35189835 DOI: 10.1186/s12885-022-09245-5] [Reference Citation Analysis]
52 Chen LY, Molina-Vila MA, Ruan SY, Su KY, Liao WY, Yu KL, Ho CC, Shih JY, Yu CJ, Yang JC, Rosell R, Yang PC. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer 2016;94:46-53. [PMID: 26973206 DOI: 10.1016/j.lungcan.2016.01.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
53 Kitadai R, Okuma Y. Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. Cancers 2022;14:2519. [DOI: 10.3390/cancers14102519] [Reference Citation Analysis]